4/4
04:30 pm
mrsn
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/19
08:09 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating. They now have a $5.00 price target on the stock.
Low
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating. They now have a $5.00 price target on the stock.
3/15
05:02 pm
mrsn
AVLX, SGH and ETNB are among pre market losers [Seeking Alpha]
Low
Report
AVLX, SGH and ETNB are among pre market losers [Seeking Alpha]
2/29
09:10 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock.
Medium
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock.
2/29
08:53 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/29
08:17 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its price target raised by analysts at Robert W. Baird from $1.00 to $5.00. They now have a "neutral" rating on the stock.
Medium
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its price target raised by analysts at Robert W. Baird from $1.00 to $5.00. They now have a "neutral" rating on the stock.
2/29
08:09 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $6.00 price target on the stock.
Medium
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $6.00 price target on the stock.
2/29
07:05 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $7.00 price target on the stock.
Low
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $7.00 price target on the stock.
2/29
07:05 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
Low
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
2/29
06:51 am
mrsn
An Intrinsic Calculation For Mersana Therapeutics, Inc. (NASDAQ:MRSN) Suggests It's 26% Undervalued [Yahoo! Finance]
Medium
Report
An Intrinsic Calculation For Mersana Therapeutics, Inc. (NASDAQ:MRSN) Suggests It's 26% Undervalued [Yahoo! Finance]
2/29
06:45 am
mrsn
Mersana Therapeutics Full Year 2023 Earnings: Revenues Disappoint [Yahoo! Finance]
Medium
Report
Mersana Therapeutics Full Year 2023 Earnings: Revenues Disappoint [Yahoo! Finance]
2/28
07:48 am
mrsn
Mersana Therapeutics Inc (MRSN) Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
High
Report
Mersana Therapeutics Inc (MRSN) Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
2/28
07:10 am
mrsn
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
High
Report
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
2/28
07:00 am
mrsn
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
High
Report
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
2/27
08:01 am
mrsn
Mersana Therapeutics to Present at Upcoming Investor Conferences
Medium
Report
Mersana Therapeutics to Present at Upcoming Investor Conferences
2/21
08:11 am
mrsn
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024 [Yahoo! Finance]
Low
Report
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024 [Yahoo! Finance]
2/21
08:00 am
mrsn
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
Low
Report
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
2/1
08:00 am
mrsn
Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference
Medium
Report
Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference